Discovery and Introduction of a New Drug for Diabetes Treatment by TUMS Researchers

Drug G2013 has been introduced as a new non-steroidal anti-inflammatory drug (NSAID) on the year 2013. Its tolerability, safety and efficacy have been assessed in preclinical evaluations and also in several clinical trials (as an additive medication to conventional drugs) on patients with rheumatoid arthritis (RA), multiple sclerosis (MS), and ankylosing spondylitis (AS) previously by the TUMS researchers.

“Following the observation of positive effects of drug G2013 on the level of blood glucose of diabetic patients participating in a clinical trial on patients with RA, MS, and AS, a distinct investigation was designed on an induced animal model of diabetes by our team for more accurate evaluation of anti-diabetic properties of this drug”; stated Dr. Mortazavi-Jahromi, one of coauthors of the research team.

Moreover, as incidence risks of atherosclerosis and its complications in diabetic patients are 2-3.5 times higher than normal individuals, the expression levels of inflammatory markers involved in these disorders were assessed in G2013-treated mice by this team.

The 28-day treatment of test group animals with drug G2013 led to the significant reduction of their fasting blood sugar level besides the considerable elevation of their fasting serum insulin level compared to the diabetic control group, which confirmed the anti-diabetic effects of drug G2013. In addition, significant decreased expression of atherosclerosis-involved inflammatory factors was observed in these mice in comparison with the diabetic control group, indicating the angio-protective properties of this drug.

“Referring to complete safety of drug G2013 in animal and human, the administrative processes are in progress for obtaining required approval and conducting clinical trial of this drug on type 1 diabetes mellitus patients”; declared Dr. Mortazavi-Jahromi.

This finding may be a breakthrough in treatment of diabetes patients since Drug G2013 has been proved as a safe agent with no or little side effects.

Dr. S.S. Mortazavi-Jahromi and Dr. A. Mirshafiey from the School of Public Health and Dr. S. Alizadeh and Dr. MH. Javanbakht from the School of Nutritional Sciences and Dietetics were involved in this research.

The article on this topic is available on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31622213